Africa News Line Friday, 04.26.2024, 6:39 AM
Welcome Guest | RSS
Site menu

Main » 2013 » April » 24
LAUSANNE, Switzerland - Wednesday, April 24th 2013 [ME NewsWire]

(BUSINESS WIRE)-- The Tobacco Products Directive (TPD) could adversely affect Europe’s economy, resulting in up to 175,000 job losses and lost tax revenue of up to EUR 5 billion throughout Europe, according to a new study published by Roland Berger Strategy Consultants.

The study, commissioned by Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM), and undertaken by Roland Berger, measures the potential economic impact of several of the proposals under consideration by the EU including standardizing the packaging and labeling of cigarettes and a ban on menthol and slim cigarettes. It concludes that these measures have the potential to reduce prices across the whole tobacco market and to fuel the illicit trade in tobacco products, resulting in significant job losses and reduction in tax revenues.

"The introduction of the new Tobacco Products Directive could significantly affect the Europea ... Read more »
Views: 398 | Added by: uaeonlinenews | Date: 04.24.2013

ME Newswire / Business Wire

MISSISSAUGA, Canada - Wednesday, April 24th 2013

Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology. Marketing licenses have been issued in 14 of the 16 European countries which are listed in the European Marketing Application for Pliaglis.

Pliaglis is a topical local anesthetic cream that uses Nuvo’s proprietary phase-changing technology to form a pliable peel on the skin when exposed to air. In the E.U. Pliaglis is indicated in adults to produce local dermal anaesthesia on intact skin prior to dermatological procedures.

Galderma launched Pliaglis in Argentina in 2011 and in the U.S. in ... Read more »
Views: 329 | Added by: uaeonlinenews | Date: 04.24.2013

SHENZHEN, China - Wednesday, April 24th 2013 [ME NewsWire]

(BUSINESS WIRE)-- ZTE Corporation ("ZTE”) (H share stock code: 0763.HK / A share stock code: 000063.SZ), a publicly-listed global provider of telecommunications equipment, network solutions and mobile devices, today announced it has been ranked No. 2 in the world in WLAN access point shipments.

According to the March 19 Gartner-published, "Market Share: Enterprise WLAN Equipment, Worldwide, 4Q12 and 2012,” ZTE held No. 2 world market share in the WLAN "coordinated access point” category at 12 per cent after it shipped 1 million units during the year.

The rapid development of ZTE’s WLAN solution is a benefit of its long-term focus on R&D and in-depth understanding of customer requirements. The explosive growth of mobile Internet has aided the application of Wi-Fi from enterprise networks to carrier networks. In turn, China Mobile has defined WLAN as its fourth network. To date, more than 3.7 million APs ... Read more »
Views: 388 | Added by: africa-live | Date: 04.24.2013

ATLANTA - Tuesday, April 23rd 2013 [ME NewsWire]

(BUSINESS WIRE)-- SIPCO, LLC is pleased to announce that SKF USA Inc., a world-wide leader in condition monitoring systems, has become a proud member of the Essential Wireless Mesh™ ("EWM”) Patent Portfolio by taking a license to the EWM Patent Portfolio.

About SIPCO, LLC

SIPCO is a leading innovator of mesh networking and related technology based in Atlanta, Georgia. Founded by renowned inventor T. David Petite, SIPCO developed technologies enabling robust self-organizing wireless networking and related technologies known as Wireless Mesh in conjunction with IntusIQ. Wireless Mesh is used in protocols such as ZigBee, Z-Wave, IEEE 802.15.4, WirelessHART and proprietary mesh network and in other wireless applications such as SmartGrid, building automation, industrial controls, network backhaul, smart vehicles, home appliances, home automation and entertainment, sensor monitoring, healthcare monitoring and Internet ser ... Read more »
Views: 285 | Added by: uaeonlinenews | Date: 04.24.2013

Companies Enter Into Agreement for Sale of GaN-On-Silicon Technology / Chip related Assets to Toshiba, with Expanded Licensing and Manufacturing Collaboration

ME Newswire / Business Wire

LIVERMORE, Calif. & TOKYO - Tuesday, April 23rd 2013

Bridgelux Inc., a leading developer and manufacturer of LED lighting technologies and solutions, and Toshiba Corporation (TOKYO:6502), a world-leading electric manufacturer, today announced that they have entered into an agreement under which Bridgelux will sell to Toshiba its industry-leading GaN-on-Silicon technology and related assets, and the companies will strengthen and extend their strategic technology collaboration, through an expanded licensing and manufacturing relationship.

In January, 2012, Bridgelux and Toshiba entered into a Joint Development and Collaboration Agreement for the development of GaN-on-Silicon LED technologies. The success of that relationship was demonstrated by Toshiba's announcements of ... Read more »
Views: 300 | Added by: uaeonlinenews | Date: 04.24.2013

INGELHEIM, Germany - Tuesday, April 23rd 2013 [ME NewsWire]

    In the Phase III clinical trial STARTVerso™1, up to 80% of patients treated with faldaprevir+ and PegIFN/RBV achieved viral cure (SVR12)
    At both doses, 87 to 89% of patients met criteria to stop all treatment after 24 weeks and 86 to 89% of these patients went on to achieve SVR12
    Faldaprevir+ was well tolerated at both doses; at the lower dose, side-effect related treatment discontinuation was similar to placebo

(BUSINESS WIRE)-For media outside USA, UK and Canada only

Results from the pivotal Phase III STARTVerso™1 trial for the investigational once-daily protease inhibitor faldaprevir+ (BI 201335), combined with pegylated interferon α2a and ribavirin (PegIFN/RBV), in treatment-naïve patients with chronic genotype-1 hepatitis C infection, will be presented at the International Liver CongressTM (ILC) in Amsterdam this week. The primary endpoint ... Read more »
Views: 301 | Added by: uaeonlinenews | Date: 04.24.2013

Search

Entries archive

Calendar